Anti-phospho Pax3, Ser201 [6A4E9] Antibody

This rat monoclonal antibody recognizes human and mouse Pax3 and its associated oncogenic fusion protein Pax3-FOXO1 only when specifically phosphorylated at Ser201.

Pax3 is a developmentally regulated transcription factor that is expressed in tissues associated with the central nervous system, craniofacial trunk, trunk neural crest, somites and skeletal muscle. Pax3 has been implicated in melanoma. Additionally, in alveolar rhabdomyosarcoma (ARMS), Pax3 is fused to the transcription factor FOXO1 to form the oncogenic fusion protein Pax3-FOXO1. Protein phosphorylation by GSK3ß at Ser201 has been implicated in the biological activity of Pax3 and the oncogenic potential of Pax3-FOXO1, making this antibody useful for studying these cancers as well as nerve and muscle development and differentiation.

From the laboratory of Andrew D. Hollenbach, PhD, LSU Health Sciences Center.

The Investigator's Annexe Part of The Investigator's Annexe program.

Catalog Number Product DataSheet Size AVAILABILITY Price Qty
Anti-phospho Pax3, Ser201 [6A4E9] Antibody
100ug In stock
Regular Price:$460.00
On Sale:

Product Type: Antibody
Antigen: Phosphorylated Ser201 of Pax3
Accession ID: P23760, P24610
Molecular Weight: 1.415 kDa
Isotype: IgG
Clonality: Monoclonal
Clone Name: 6A4E9
Reactivity: Human, mouse
Immunogen: Peptide-KLH conjugate: KLH-CSERASAPQ(pSer)DEG
Species Immunized: Rat
Purification Method: Protein G
Buffer: 0.1M Sodium Phosphate, pH 7.4, 0.15M NaCl, 0.05% (w/v) Sodium Azide
Tested Applications: WB (1:2000)
Concentration: 1 mg/mL
Storage: -20C
Shipped: Cold packs


Representative antibody recognition of Pax3(p201) by Western Blot

Pax3 WB

Bacterially expressed and purified wild-type GST-Pax3 was used as purified (left lanes) or was phosphorylated using an in vitro kinase assay and non-radioactive ATP (right lanes). The proteins were used for Western blot analysis using the anti-Pax3(p201) polyclonal antibody. A Coomassie stained gel demonstrates the presence of equal amounts of protein in the assay (top panel).

Adapted from: Dietz KN, et al. Int J Biochem Cell Biol. 2011 Jun;43(6):936-45.

From the laboratory of Andrew D. Hollenbach, PhD, LSU Health Sciences Center.
  1. Dietz KN, Miller PJ, Iyengar AS, Loupe JM, Hollenbach AD. Identification of serines 201 and 209 as sites of Pax3 phosphorylation and the altered phosphorylation status of Pax3-FOXO1 during early myogenic differentiation. Int J Biochem Cell Biol. 2011 Jun;43(6):936-45.
  2. Loupe JM, Miller PJ, Ruffin DR, Stark MW, Hollenbach AD. Inhibiting phosphorylation of the oncogenic PAX3-FOXO1 reduces alveolar rhabdomyosarcoma phenotypes identifying novel therapy options. Oncogenesis. 2015 Mar 30;4:e145. doi: 10.1038/oncsis.2015.2.

If you publish research with this product, please let us know so we can cite your paper.